Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro

Details for Australian Patent Application No. 2010306940 (hide)

Owner Smith Holdings, LLC

Inventors Smith, Larry J.

Agent Fisher Adams Kelly

Pub. Number AU-A-2010306940

PCT Pub. Number WO2011/046983

Priority 61/250,714 12.10.09 US

Filing date 12 October 2010

Wipo publication date 21 April 2011

International Classifications

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

7 June 2012 PCT application entered the National Phase

  PCT publication WO2011/046983 Priority application(s): WO2011/046983

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010306954-CGRP receptor antagonists

2010306930-Marking paper products